Nothing Special   »   [go: up one dir, main page]

IN163200B - - Google Patents

Info

Publication number
IN163200B
IN163200B IN464/CAL/86A IN464CA1986A IN163200B IN 163200 B IN163200 B IN 163200B IN 464CA1986 A IN464CA1986 A IN 464CA1986A IN 163200 B IN163200 B IN 163200B
Authority
IN
India
Application number
IN464/CAL/86A
Other languages
English (en)
Inventor
Nandini Katre
Michael J Knauf
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of IN163200B publication Critical patent/IN163200B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IN464/CAL/86A 1985-06-26 1986-06-23 IN163200B (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74995585A 1985-06-26 1985-06-26
PCT/US1986/001252 WO1987000056A1 (fr) 1985-06-26 1986-06-06 Solubilisation de proteines pour des compositions pharmaceutiques utilisant une conjugaison de polymeres

Publications (1)

Publication Number Publication Date
IN163200B true IN163200B (fr) 1988-08-20

Family

ID=25015921

Family Applications (1)

Application Number Title Priority Date Filing Date
IN464/CAL/86A IN163200B (fr) 1985-06-26 1986-06-23

Country Status (17)

Country Link
EP (1) EP0229108B1 (fr)
JP (1) JP2524586B2 (fr)
KR (1) KR900004801B1 (fr)
CA (1) CA1291708C (fr)
DE (1) DE3676670D1 (fr)
DK (1) DK169874B1 (fr)
FI (1) FI93424C (fr)
GR (1) GR861641B (fr)
IE (1) IE59406B1 (fr)
IL (1) IL79235A (fr)
IN (1) IN163200B (fr)
MX (1) MX174442B (fr)
NZ (1) NZ216618A (fr)
PH (1) PH25004A (fr)
PT (1) PT82834B (fr)
WO (1) WO1987000056A1 (fr)
ZA (1) ZA864766B (fr)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
CA1283046C (fr) * 1986-05-29 1991-04-16 Nandini Katre Facteur de necrose des tumeurs
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
WO1990015628A1 (fr) * 1989-06-14 1990-12-27 Cetus Corporation Conjugue polymere antibiotique
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
WO1991001758A1 (fr) * 1989-08-07 1991-02-21 Debiopharm S.A. Derives polymeres de subtances medicamenteuses biologiquement actifs
US5393735A (en) * 1990-08-09 1995-02-28 Rohm And Haas Company Herbicidal glutarimides
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
FR2658521B1 (fr) * 1990-02-19 1994-01-21 Serbioo Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
FR2658519B1 (fr) * 1990-02-19 1995-07-07 Serbio Substrats peptidiques pour identification du facteur xa.
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5312903A (en) * 1990-06-01 1994-05-17 E. I. Du Pont De Nemours And Company Lysine-glycosylated recombinant interleukin-2
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
DK0642798T3 (da) * 1993-09-08 2007-09-10 Jolla Pharma Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
EP0824541B1 (fr) * 1995-05-04 2009-12-16 Gilead Sciences, Inc. Complexes de ligands d'acide nucleique
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
CA2229435A1 (fr) * 1995-09-14 1997-03-20 Lxr Biotechnology Inc. Compositions ayant une activite anti-apoptotique et contenant un melange de phospholipides
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2275300T3 (es) * 1997-01-15 2007-06-01 Phoenix Pharmacologics, Inc. Factor de necrosis tumoral modificado.
EP0973384A4 (fr) 1997-02-13 2004-10-13 Sky High Llc Solution de preservation d'organes
TR200003161T2 (tr) * 1998-04-28 2001-01-22 Applied Research Systems Ars Holding N.V. Poliol-IFN-Beta konjugatları
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
DK2316475T3 (da) 1998-08-06 2017-11-20 Mountain View Pharmaceuticals Inc Isoleret tetramer urikase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EA005005B1 (ru) 1998-10-16 2004-10-28 Байоджен, Инк. ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
NZ510689A (en) * 1998-10-16 2003-07-25 Biogen Inc Polymer conjugates of interferon beta-1a and uses
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CA2380760A1 (fr) * 1999-08-27 2001-03-08 Maxygen Aps Nouvelles molecules analogues a l'interferon beta
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
TR200101086A3 (fr) * 1999-10-15 2001-08-21
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
WO2001036001A2 (fr) 1999-11-12 2001-05-25 Maxygen Holdings Ltd Conjugues d'interferon gamma
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
CA2397347C (fr) 2000-02-11 2011-07-12 Maxygen Aps Molecules de type facteur vii ou viia
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
WO2003000278A1 (fr) * 2001-06-22 2003-01-03 Kyowa Hakko Kogyo Co., Ltd. Onguents
DK1414471T3 (da) 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
EP2279753B1 (fr) 2001-10-10 2015-09-16 Novo Nordisk A/S Remodelage et gluco-conjugaison de peptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
EP2305313B1 (fr) 2001-10-10 2014-03-26 ratiopharm GmbH Remodelage et glycoconjugation d' interféron alpha (IFNa)
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
AU2003210564B2 (en) 2002-01-18 2008-10-23 Biogen Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
CA2490360A1 (fr) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Glycoformes du facteur vii pegylees
CA2491178A1 (fr) 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Variants polypeptidiques a interferon gamma pleine longueur
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
EP1608688B1 (fr) 2003-03-14 2013-02-27 BioGeneriX AG Polymeres hydrosolubles ramifies et conjugues de ceux-ci
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1613261A4 (fr) 2003-04-09 2011-01-26 Novo Nordisk As Formation intracellulaire de conjugues de peptides
JP4674702B2 (ja) 2003-04-09 2011-04-20 バイオジェネリクス エージー グリコペギレ−ション法およびその方法により生成されたタンパク質／ペプチド
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
ES2405209T3 (es) * 2003-08-07 2013-05-30 Zymogenetics, Inc. Preparaciones homogéneas de lL-29
JP4850514B2 (ja) 2003-08-25 2012-01-11 東レ株式会社 インターフェロンβ複合体
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
EP2633866A3 (fr) 2003-10-17 2013-12-18 Novo Nordisk A/S Thérapie combinée
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06005732A (es) 2003-11-24 2006-08-17 Neose Technologies Inc Eritropoyetina glucopegilada.
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
BRPI0510295A (pt) 2004-05-04 2007-11-06 Novo Nordisk Healthcare Ag preparação de uma glicoproteìna, e, método para produzir a mesma
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
EP1771066A2 (fr) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
EP1799249A2 (fr) 2004-09-10 2007-06-27 Neose Technologies, Inc. Interferon alpha glycopegyle
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
RU2304586C1 (ru) * 2006-03-27 2007-08-20 Михаил Николаевич Смирнов Препарат интерлейкина-2 и способ его получения
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
EP2213733A3 (fr) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Analogues de facteur IX ayant une demi-vie prolongée in vivo
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2615108B1 (fr) 2006-09-08 2016-10-26 Ambrx, Inc. Polypeptide plasmatique humain modifié ou échafaudages fc et leur utilisations
JP2010503630A (ja) * 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
JP2010523582A (ja) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
WO2009027437A1 (fr) 2007-08-27 2009-03-05 Biogenerix Ag Preparation liquide de conjugue de g-csf
EP2930182A1 (fr) 2007-11-20 2015-10-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
BRPI0905707B1 (pt) * 2008-01-18 2024-02-27 Dow Global Technologies Inc Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
ES2539124T3 (es) 2008-01-22 2015-06-26 Araim Pharmaceuticals, Inc. Péptidos y análogos peptídicos protectores de tejido para la prevención y el tratamiento de enfermedades y trastornos asociados con daño tisular
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
EP2672259A1 (fr) 2008-05-13 2013-12-11 Advanced Liquid Logic, Inc. Procédés, systèmes et dispositifs associés à un positionneur de gouttelettes
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
KR101732054B1 (ko) 2008-09-26 2017-05-02 암브룩스, 인코포레이티드 비천연 아미노산 복제 의존성 미생물 및 백신
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
PE20121799A1 (es) 2009-12-21 2013-01-02 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos
EP2542569B1 (fr) 2010-03-05 2020-09-16 Omeros Corporation Molécules chimériques inhibitrices d'activation du complément
WO2011143274A1 (fr) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptides inhibiteurs de vla4
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
KR20200070407A (ko) * 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
TWI666027B (zh) 2011-02-10 2019-07-21 羅齊克雷雅公司 突變介白素-２多肽
MX2014000031A (es) 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
CN104136038A (zh) 2012-02-29 2014-11-05 东丽株式会社 体腔积液抑制剂
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013185115A1 (fr) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP3336103B1 (fr) 2013-07-10 2021-03-17 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels sitespécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
AU2015335603B2 (en) 2014-10-24 2020-04-30 Bristol-Myers Squibb Company Modified FGF-21 polypeptides and uses thereof
WO2017189988A1 (fr) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Peptides protecteurs tissulaires permettant de prévenir et traiter des maladies et des troubles associés à une lésion tissulaire
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN110382525B (zh) 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
US20210060169A1 (en) * 2017-12-27 2021-03-04 Kyowa Kirin Co., Ltd. Il-2 variant
HUE065882T2 (hu) 2018-09-11 2024-06-28 Ambrx Inc Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020158691A1 (fr) 2019-01-28 2020-08-06 東レ株式会社 Corps modifié de polyéthylène glycol pour facteur de croissance des hépatocytes ou fragment actif associé
BR112021012880A2 (pt) 2019-01-28 2021-11-16 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento
MX2021009644A (es) 2019-02-12 2021-09-08 Ambrx Inc Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021209402A2 (fr) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugués
TW202207975A (zh) 2020-05-11 2022-03-01 瑞士商赫孚孟拉羅股份公司 使用經修飾之ｐｂｍｃ及免疫結合體之組合療法
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
AU2021393752A1 (en) 2020-12-04 2023-05-18 F. Hoffmann-La Roche Ag Ph-dependent mutant interleukin-2 polypeptides
WO2022148853A1 (fr) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugués
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
WO2023052541A1 (fr) 2021-09-30 2023-04-06 Imcheck Therapeutics Combinaison d'un anticorps d'activation anti-btn3a et d'un agoniste il-2 en vue d'une utilisation en thérapie
WO2023062050A1 (fr) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Nouveaux immunoconjugués d'interleukine-7
WO2023062048A1 (fr) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Immunoconjugués de pd1-il7v alternatifs pour le traitement du cancer
WO2024153725A1 (fr) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Polypeptides variants de domaine fc-il2 recombinants et polythérapie avec des polypeptides de liaison à l'antigène ancrés sur une membrane

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS54157816A (en) * 1978-05-27 1979-12-13 Unitika Ltd Fixing of bioactive substance to solid surface
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
EP0098110B1 (fr) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Composition à action prolongée
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof

Also Published As

Publication number Publication date
KR870000423A (ko) 1987-02-18
IL79235A (en) 1991-01-31
PH25004A (en) 1991-01-28
CA1291708C (fr) 1991-11-05
DK97987A (da) 1987-02-25
PT82834A (en) 1986-07-01
PT82834B (pt) 1988-12-15
IE59406B1 (en) 1994-02-23
FI870809A (fi) 1987-02-25
IE861706L (en) 1986-12-26
EP0229108B1 (fr) 1990-12-27
DK169874B1 (da) 1995-03-20
EP0229108A1 (fr) 1987-07-22
IL79235A0 (en) 1986-09-30
NZ216618A (en) 1989-05-29
FI93424B (fi) 1994-12-30
FI93424C (fi) 1995-04-10
KR900004801B1 (ko) 1990-07-06
ZA864766B (en) 1988-02-24
MX174442B (es) 1994-05-17
FI870809A0 (fi) 1987-02-25
JP2524586B2 (ja) 1996-08-14
WO1987000056A1 (fr) 1987-01-15
JPS62503171A (ja) 1987-12-17
GR861641B (en) 1986-09-12
DE3676670D1 (de) 1991-02-07
DK97987D0 (da) 1987-02-25

Similar Documents

Publication Publication Date Title
IN163200B (fr)
IN164088B (fr)
DE3590846T1 (fr)
IN164599B (fr)
DE3690056T1 (fr)
IN165167B (fr)
IN162439B (fr)
IN162517B (fr)
IN163197B (fr)
IN163937B (fr)
IN165022B (fr)
BG45436A1 (fr)
BG44892A1 (fr)
BG45260A1 (fr)
BG45251A1 (fr)
BG45244A1 (fr)
BG45438A1 (fr)
BG45466A1 (fr)
BG45210A1 (fr)
BG45195A1 (fr)
BG45177A1 (fr)
BG45174A1 (fr)
BG45137A1 (fr)
BG45110A1 (fr)
BG44989A1 (fr)